Active substances
Amoxicillin + Clarithromycin + Lansoprazole
- US FDA 4
- Health Canada 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED) | 500MG;500MG;30MG | capsule, tablet, capsule, delayed rel pellets · oral | SANDOZ | Prescription | 4 Mar 2014 |
| LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED) | 500MG;500MG;30MG | capsule, tablet, capsule, delayed rel pellets · oral | RISING | Prescription | 7 Oct 2016 |
| PREVPAC (COPACKAGED) | 500MG;500MG;30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule, tablet, capsule, delayed rel pellets · oral | TAKEDA PHARMS USA | Discontinued | 2 Dec 1997 |
| LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED) | 500MG;500MG;30MG | capsule, tablet, capsule, delayed rel pellets · oral | ANI PHARMS | Discontinued | 30 Aug 2013 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AA-LANSOPRAZOLE-AMOXICILLIN-CLARITHROMYCIN | 02470780 | 500 MG / CAP; 30 MG / CAP; 500 MG / TAB | KIT; TABLET; CAPSULE (DELAYED-RELEASE); CAPSULE · ORAL | AA PHARMA INC |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.